Propranolol for hemangiomas doesn't impair infant growth

Propranolol for hemangiomas doesn't impair infant growth

(HealthDay)—For infantile hemangiomas, systemic propranolol appears safe and does not impair physical growth, according to a study published online March 6 in the Journal of Dermatology.

Li Hu, from the Shanghai Jiao Tong University School of Medicine, and colleagues examined complications associated with systemic propranolol therapy for . Propranolol was given at 2 mg/kg per day. During therapy, abnormal symptoms and growth parameters were recorded; 76 patients with complete growth parameters were included in the study. Patients were followed at least through age 2 years.

The researchers identified minor complications of propranolol, including sleeping disorders, diarrhea, decrease in fasting glucose, bronchial hyperactivity, and hyperkalemia. During , four (5.26 percent) patients' growth curves dropped off more than 20 percentiles; after medication withdrawal half returned to normal. When medication was stopped, none of the suffered from underweight, wasting, or stunning.

"Systemic propranolol was proved to be a safe treatment for problematic infantile hemangiomas and did not affect the physical growth," the authors write.

Explore further

Propranolol seems prophylactic against infantile hemangiomas

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Propranolol for hemangiomas doesn't impair infant growth (2016, March 21) retrieved 24 May 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors